370 related articles for article (PubMed ID: 30230171)
41. Brain abnormalities in tuberous sclerosis complex.
DiMario FJ
J Child Neurol; 2004 Sep; 19(9):650-7. PubMed ID: 15563010
[TBL] [Abstract][Full Text] [Related]
42. Analysis of twenty pediatric cases of tuberous sclerosis complex: are we doing enough?
Nath J; Dubey A; Pavan R
Indian J Dermatol Venereol Leprol; 2015; 81(1):23-8. PubMed ID: 25566892
[TBL] [Abstract][Full Text] [Related]
43. Tuberous sclerosis complex: Imaging characteristics in 11 cases and review of the literature.
Hu S; Hu DY; Zhu WZ; Wang L; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):601-606. PubMed ID: 27465340
[TBL] [Abstract][Full Text] [Related]
44. A Case of Tuberous Sclerosis Without Multiorgan Involvement.
Falsafi P; Taghavi-Zenouz A; Khorshidi-Khiyavi R; Nezami N; Estiar MA
Glob J Health Sci; 2015 Feb; 7(5):124-31. PubMed ID: 26156917
[TBL] [Abstract][Full Text] [Related]
45. Tuberous sclerosis complex: the past and the future.
De Waele L; Lagae L; Mekahli D
Pediatr Nephrol; 2015 Oct; 30(10):1771-80. PubMed ID: 25533384
[TBL] [Abstract][Full Text] [Related]
46. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
47. [Diagnosis of tuberous sclerosis complex focusing on prenatal period].
Filipová H; Procházka M; Vrtěl R
Ceska Gynekol; 2016 Apr; 81(2):147-54. PubMed ID: 27457398
[TBL] [Abstract][Full Text] [Related]
48. The clinical and paraclinical manifestations of tuberous sclerosis complex in children.
Barzegar M; Poorshiri B; Yousefi L; Raeisi S; Bakhtiary H; Eftekhari Milani A; Ebadi Z
Acta Neurol Belg; 2022 Apr; 122(2):385-390. PubMed ID: 33738777
[TBL] [Abstract][Full Text] [Related]
49. Tuberous sclerosis complex and DNA repair.
Habib SL
Adv Exp Med Biol; 2010; 685():84-94. PubMed ID: 20687497
[TBL] [Abstract][Full Text] [Related]
50. Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex.
Rovira À; Ruiz-Falcó ML; García-Esparza E; López-Laso E; Macaya A; Málaga I; Vázquez É; Vicente J
J Neurooncol; 2014 Jun; 118(2):205-223. PubMed ID: 24771286
[TBL] [Abstract][Full Text] [Related]
51. Tuberous sclerosis complex: review based on new diagnostic criteria.
Portocarrero LKL; Quental KN; Samorano LP; Oliveira ZNP; Rivitti-Machado MCDM
An Bras Dermatol; 2018 Jun; 93(3):323-331. PubMed ID: 29924239
[TBL] [Abstract][Full Text] [Related]
52. The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey.
Skalicky AM; Rentz AM; Liu Z; Wheless JW; Pelletier CL; Dunn DW; Frost MD; Nakagawa J; Magestro M; Prestifilippo J; Pashos C
J Child Neurol; 2015 Apr; 30(5):563-9. PubMed ID: 24667738
[TBL] [Abstract][Full Text] [Related]
53. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy.
Wheless JW
Epilepsy Behav Case Rep; 2015; 4():63-6. PubMed ID: 26543807
[TBL] [Abstract][Full Text] [Related]
54. Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention.
Wheless JW; Klimo P
J Child Neurol; 2014 Nov; 29(11):1562-71. PubMed ID: 24105488
[TBL] [Abstract][Full Text] [Related]
55. Mammalian target of rapamycin inhibitors for the treatment of astrocytic hamartoma in tuberous sclerosis complex (TSC).
Vorobichik Berar O; Tzadok M; Zloto O; Moroz I; Hecht I; Musika AA; Shlomovitz O; Fabian ID; Vishnevskia Dai V
Graefes Arch Clin Exp Ophthalmol; 2022 Sep; 260(9):3061-3068. PubMed ID: 35230473
[TBL] [Abstract][Full Text] [Related]
56. Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex.
Boer K; Troost D; Timmermans W; Gorter JA; Spliet WG; Nellist M; Jansen F; Aronica E
Neuroscience; 2008 Sep; 156(1):203-15. PubMed ID: 18706978
[TBL] [Abstract][Full Text] [Related]
57. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
58. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
García-Peñas JJ; Carreras-Sááez I
Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
[TBL] [Abstract][Full Text] [Related]
59. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.
Kingswood JC; d'Augères GB; Belousova E; Ferreira JC; Carter T; Castellana R; Cottin V; Curatolo P; Dahlin M; de Vries PJ; Feucht M; Fladrowski C; Gislimberti G; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Nabbout R; O'Callaghan F; Benedik MP; Qin J; Marques R; Sander V; Sauter M; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2017 Jan; 12(1):2. PubMed ID: 28057044
[TBL] [Abstract][Full Text] [Related]
60. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
